| Rank |
Pathway / Axis |
Cancer Cells (↑ / ↓ / ↔) |
Normal Cells (↑ / ↓ / ↔) |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
NRF2 / KEAP1 axis |
↔ / ↑ cytoprotection (context-dependent; resistance risk) |
↑ antioxidant defense (protective) |
P→G |
Stress-response activation |
Electrophilic quinone form modifies KEAP1 cysteines; protective in normal tissue but may enhance survival in NRF2-driven tumors. |
| 2 |
ROS |
↑ ROS (dose-dependent; high concentration) → apoptosis |
↓ oxidative damage (low–moderate dose) |
P/R |
Redox bifunctionality |
Acts as antioxidant at low stress; can become pro-oxidant in metabolically stressed cancer cells. |
| 3 |
PI3K / AKT / mTOR |
↓ signaling (model-dependent) |
↔ |
R/G |
Proliferation suppression |
Reported in breast, prostate, leukemia models; downstream cell-cycle arrest. |
| 4 |
STAT3 |
↓ phosphorylation/activity (model-dependent) |
↔ |
R/G |
Growth and survival inhibition |
Relevant in inflammation-driven or STAT3-addicted tumors. |
| 5 |
HIF-1α / Warburg axis |
↓ HIF-1α (model-dependent) |
↔ |
G |
Hypoxia signaling suppression |
Reported reduction of glycolytic adaptation under hypoxic conditions in some models. |
| 6 |
Ca²⁺ (ER stress linkage) |
↑ ER stress–linked Ca²⁺ signaling (model-dependent) |
↔ / protective |
P/R |
Apoptosis induction (subset) |
Often secondary to ROS elevation and mitochondrial perturbation. |
| 7 |
Ferroptosis |
↔ / ↑ (model-dependent; lipid ROS context) |
↓ lipid peroxidation (low dose) |
R/G |
Lipid redox modulation |
Antioxidant capacity may oppose ferroptosis at low dose; oxidative conversion could promote it under stress. |
| 8 |
Clinical Translation Constraint |
Most anti-cancer data at 10–50 µM in vitro; systemic exposure from dietary intake likely below these levels. NRF2 activation could theoretically protect tumor cells in certain contexts. |
— |
PK-limited; preclinical stage |
Consider tumor NRF2 status and dose when interpreting translational relevance. |
| Rank |
Pathway / Axis |
AD Brain (↑ / ↓ / ↔) |
Normal Brain (↑ / ↓ / ↔) |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
NRF2 activation |
↑ antioxidant gene expression |
↑ protective |
P→G |
Neuroprotection |
Well-supported in preclinical models; CA described as a pro-electrophilic NRF2 activator. |
| 2 |
ROS |
↓ oxidative stress |
↓ oxidative burden |
P/R |
Mitochondrial protection |
Particularly relevant in oxidative neurodegenerative models. |
| 3 |
Neuroinflammation (NF-κB) |
↓ inflammatory signaling |
↓ inflammatory tone |
R/G |
Anti-inflammatory |
Reported microglial modulation in models. |
| 4 |
Aβ toxicity modulation |
↓ Aβ-induced toxicity (model-dependent) |
↔ |
R/G |
Neuronal survival support |
Preclinical evidence only; no large human RCT confirmation. |
| 5 |
Clinical Translation Constraint |
Primarily preclinical neuroprotection data; human AD efficacy not yet established in large RCTs. |
— |
Early translational stage |
Mechanistically plausible but clinically unproven. |